Centre National De La Recherche Scientifique

Université De Lausanne

Other

Phi Pharma Sa

Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii

Ludwig Institute for Cancer Research Limited

University of Lausanne

Azienda Ospedaliera Papa Giovanni Xxiii

Chuv—centre Hospitalier Universitaire Vaudois

Sib Swiss Institute of Bioinformatics

Jean Kadouche

Kadouche, Jean

Vincent Zoete

Olivier Michielin

Martine Cerutti

Jean-Pierre Mach

Josee Golay

Justyna Iwaszkiewicz

Sylvie Choblet

Christophe Bonny

Fabrice Chenaux

Nahzli Dilek

George Coukos

Melita Irving

Kelly Ascencao

Patrick Reichenbach

Josée Golay

The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CHI and CL domains, said mutations preventing heavy chain/light chain mispairing.

Multispecific antigens binding fragments and multspecific antibodies

The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.

Multispecific antigens binding fragments and multispecific antibodies

The present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, methods of reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.

Kinase mutants and uses thereof

Multispecific antigen binding fragments and multispecific antibodies derived therefrom comprising mutant CH1 and CL-kappa domains

The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, keratan sulfate. The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of keratan-sulfate expressing cells in vitro and in vivo.

Keratan sulfate specific transporter molecules

The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides or polypeptides, that function as transporter moieties or compositions specifically recognizing the proteoglycan, chondroitin 6-sulfate (C6S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C6S expressing cells in vitro and in vivo.

C6S specific transporter molecules

The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.

Multispecific antigens binding fragments and multispecific antibodies derived therefrom comprising mutant CH1 and CL-&#x3ba; domains

Growing community of inventors

Morges, Switzerland

Vincent Zoete